Boundless Bio, Inc.
$1.6
▼
-4.42%
2026-04-21 05:45:00
boundlessbio.com
NMS: BOLD
Explore Boundless Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$35.4 M
Current Price
$1.6
52W High / Low
$1.78 / $0.96
Stock P/E
—
Book Value
$4.4
Dividend Yield
—
ROCE
-43.97%
ROE
-46.69%
Face Value
—
EPS
$-2.6
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
28
Beta
-0.26
Debt / Equity
49.7
Current Ratio
8.74
Quick Ratio
8.74
Forward P/E
-0.88
Price / Sales
—
Enterprise Value
$-33.23 M
EV / EBITDA
0.53
EV / Revenue
—
Rating
None
Target Price
$4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Allogene Therapeutics, Inc. | $2.42 | — | $582.63 M | — | -53.97% | -53.42% | $4.46 / $0.86 | $1.27 |
| 2. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
| 3. | Cullinan Therapeutics, Inc. | $14.52 | — | $911.52 M | — | -58.85% | -44.02% | $16.74 / $5.68 | $6.79 |
| 4. | Traws Pharma, Inc. | $1.39 | — | $14.12 M | — | -185.49% | -10.6% | $3.27 / $0.97 | $0.64 |
| 5. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
| 6. | MAIA Biotechnology, Inc. | $1.41 | — | $81.91 M | — | -618.06% | -7.45% | $3.19 / $0.87 | $0.06 |
| 7. | PolyPid Ltd. | $4.69 | — | $89.5 M | — | -226.3% | -3.66% | $5.12 / $2.44 | $0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -14 M | -15.15 M | -17.06 M | -17.34 M | -18.28 M | — |
| Net Profit | -12.88 M | -13.88 M | -15.68 M | -15.76 M | -16.45 M | — |
| EPS in Rs | -0.58 | -0.62 | -0.7 | -0.7 | -0.73 | -0.74 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -63.55 M | -73.27 M | -54.8 M | -46.47 M |
| Net Profit | -58.2 M | -65.36 M | -49.43 M | -45.9 M |
| EPS in Rs | -2.6 | -2.92 | -2.21 | -2.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 157.06 M | 206.41 M | 129.89 M | 76.83 M |
| Total Liabilities | 58.41 M | 55.77 M | 256.98 M | 158.53 M |
| Equity | 98.65 M | 150.64 M | -127.08 M | -81.7 M |
| Current Assets | 109.61 M | 154.39 M | 124.2 M | 68.04 M |
| Current Liabilities | 12.54 M | 8.13 M | 9.36 M | 7.73 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -46.66 M | -60.84 M | -46.85 M | -39.6 M |
| Investing CF | 37.8 M | -26.1 M | -38.26 M | 16.13 M |
| Financing CF | 0.14 M | 89.82 M | 97.9 M | 0.13 M |
| Free CF | -47.21 M | -63.38 M | -47.49 M | -40.66 M |
| Capex | -0.55 M | -2.54 M | -0.63 M | -1.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -32.22% | -7.7% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.